Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? - A literature-based meta-analysis

被引：21

作者：

Xu, Chongrui

Zhou, Qing

Wu, Yi-long ^{[1
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷

关键词：

Non-small cell lung cancer; Target therapy; Chemotherapy; Meta-analysis; OPEN-LABEL; PHASE-III; STANDARD CHEMOTHERAPY; 1ST-LINE TREATMENT; GEFITINIB IRESSA; ERLOTINIB; DOCETAXEL; MULTICENTER; MUTATIONS; TRIAL;

D O I：

10.1186/1756-8722-5-62

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receiving chemotherapy. Some trials treated patients with TKI according to their clinical characteristics. A few studies only chose patients with an epidermal grouth factor receptor (EGFR) mutation for TKI therapy. We aimed to determine whether patients could be treated with TKIs based on clinical factors in the first-line setting. Methods: We performed a meta-analysis of randomized trials involving patients with advanced NSCLC treated with chemotherapy or TKIs by different selections. Efficacy outcomes of interest were the objective response rate (ORR), progression-free survival (PFS) and the overall survival (OS) of each treatment arm. Results: Four trials enrolled unselected patients, and two trials selected East Asian patients using the clinical factors of gender and smoking history. Five trials chose patients with an EGFR mutation who were randomized for treatment with TKI or chemotherapy. For unselected patients, the risk ratio (RR) of the ORR was 3.52, the hazard ratio (HR) of the PFS was 1.29 and the HR of the OS was 1.35. For the clinically selected patients, the RR of the ORR was 0.64. The HRs of the PFS and OS were 0.83 and 0.92, respectively. The ORR and PFS were better for TKIs than for chemotherapy in patients with an EGFR mutation. The ORR was 0.47, and the HRs of the PFS and OS were 0.36 and 1.00, respectively. Conclusions: Advanced NSCLC patients with an EGFR mutation benefit most from TKIs. EGFR-TKI treatment is justified for patients with unknown EGFR status, and those who cannot tolerate chemotherapy owing to age, poor performance status (PS) or other medical conditions, when selected according to clinical factors in the first-line setting.

引用

页数：9

共 24 条

[11] Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 [J].

Lilenbaum, Rogerio ;

Axelrod, Rita ;

Thomas, Sachdev ;

Dowlati, Afshin ;

Seigel, Leonard ;

Albert, Donald ;

Witt, Karsten ;

Botkin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :863-869

[12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[13] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[14] Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer [J].

Maruyama, Riichiroh ;

Nishiwaki, Yutaka ;

Tamura, Tomohide ;

Yamamoto, Nobuyuki ;

Tsuboi, Masahiro ;

Nakagawa, Kazuhiko ;

Shinkai, Tetsu ;

Negoro, Shunichi ;

Imamura, Fumio ;

Eguchi, Kenji ;

Takeda, Koji ;

Inoue, Akira ;

Tomii, Keisuke ;

Harada, Masao ;

Masuda, Noriyuki ;

Jiang, Haiyi ;

Itoh, Yohji ;

Ichinose, Yukito ;

Saijo, Nagahiro ;

Fukuoka, Masahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4244-4252

[15] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[16] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[17] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[18] Meta-analyses of randomised clinical trials in oncology [J].

Pignon, Jean-Pierre ;

Hill, Catherine .

LANCET ONCOLOGY, 2001, 2 (08) :475-482

[19] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[20] Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer A Combined Clinical-Molecular Pathological Approach [J].

Salto-Tellez, Manuel ;

Tsao, Ming-Sound ;

Shih, Jin-Yuan ;

Thongprasert, Sumitra ;

Lu, Shun ;

Chang, Gee-Chen ;

Au, Joseph Siu-Kie ;

Chou, Teh-Ying ;

Lee, Jong-Seok ;

Shi, Yuan-Kai ;

Radzi, Ahmad ;

Kang, Jin-Hyoung ;

Kim, Sang-We ;

Tan, Soo-Yong ;

Yang, James Chih-Hsin .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (10) :1663-1669

← 1 2 3 →